Literature DB >> 11050029

Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

A Schrag1, N Quinn.   

Abstract

We investigated the prevalence of dyskinesias and motor fluctuations, and the factors determining their occurrence, in a community-based population of patients with Parkinson's disease. Among 124 patients with Parkinson's disease, 87 (70%) had received a levodopa preparation. Among these 87 patients, 28% were experiencing treatment-induced dyskinesias and 40% response fluctuations. The prevalence of motor fluctuations was best predicted by disease duration and dose of levodopa, whereas dyskinesias could be best predicted by duration of treatment. Patients with a shorter time from symptom onset to initiation of levodopa and younger patients had developed motor complications earlier, and patients who had started treatment with a dopamine agonist had developed these treatment complications later. Although a satisfactory response to medication was associated with higher rates of motor complications, poor or moderate response was associated with lower quality of life in patients with a disease duration of </=5 years or >/=10 years. We conclude that motor fluctuations are most strongly related to disease duration and dose of levodopa, and dyskinesias to duration of levodopa treatment. However, poorer quality of life associated with inadequate dosage of levodopa may be the price for a low rate of motor complications in patients with Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050029     DOI: 10.1093/brain/123.11.2297

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  150 in total

Review 1.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 2.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

3.  Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease.

Authors:  O K Sujith; Carol Lane
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

4.  Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson's disease.

Authors:  Giovanni Abbruzzese; Angelo Antonini; Paolo Barone; Fabrizio Stocchi; Tiziano Tamburini; Laura Bernardi; Marianna Amboni; Laura Vacca; Valeria Posocco; Delia Colombo
Journal:  Neurol Sci       Date:  2012-02-04       Impact factor: 3.307

Review 5.  Late-stage Parkinson disease.

Authors:  Miguel Coelho; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

6.  Improving symptom control in early Parkinson's disease.

Authors:  Stuart H Isaacson; Robert A Hauser
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

7.  Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up.

Authors:  W M M Schüpbach; N Chastan; M L Welter; J L Houeto; V Mesnage; A M Bonnet; V Czernecki; D Maltête; A Hartmann; L Mallet; B Pidoux; D Dormont; S Navarro; P Cornu; A Mallet; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

8.  Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

Authors:  A A Martinez; M G Morgese; A Pisanu; T Macheda; M A Paquette; A Seillier; T Cassano; A R Carta; A Giuffrida
Journal:  Neurobiol Dis       Date:  2014-12-05       Impact factor: 5.996

9.  Assessment of Wearing Off in Parkinson's disease using objective measurement.

Authors:  Parisa Farzanehfar; Holly Woodrow; Malcolm Horne
Journal:  J Neurol       Date:  2020-09-15       Impact factor: 4.849

Review 10.  Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.

Authors:  Angelo Antonini; K Ray Chaudhuri; Pablo Martinez-Martin; Per Odin
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.